NEWSROOM Press Releases

    254 Results

    Biodesix Announces New Clinical Data Demonstrating VeriStrat Testing Predicts Survival in Advanced NSCLC and Immunotherapy

    Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test.

    Biodesix Highlights Pipeline and Companion Diagnostic Development at World CDx and RAS-Targeted Drug Discovery

    Biodesix highlighted their development and commercialization of companion diagnostics for directing the treatment of non-small cell lung cancer at the 2019 Clinical Biomarkers & World CDx Conference.

    Biodesix Adds Dr. Robert Georgantas III to Executive Leadership Team

    Biodesix appointed Robert W. Georgantas III, Ph.D., as the company’s Senior Vice President (SVP) of Research and Translational Science.

    Biodesix Names Dr. James Jett Chief Medical Officer

    Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer.

    Biodesix, Immodulon Collaborating on Pancreatic Cancer Biomarkers

    Biodesix announced that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.

    Biodesix Adds Dr. Charles Watts to Board of Directors

    Biodesix announces the appointment of Charles Watts, M.D. to the company’s board of directors.


    Biodesix Secures U.S. Patent for Proprietary Blood Specimen Collection Device

    Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD).

    Biodesix Completes Acquisition of Oncimmune Assets in the United States

    Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States.


    Biodesix Appoints Scott Hutton as Chief Executive Officer

    Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020.


    Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

    Biodesix, Inc. today announced that Tri-Star Health in Nashville, TN is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management.

    1 2